Find new investment opportunities based on Market Sentiment Indicator. Manage watchlist risk with leading indicator of volatility See what influential analysts and investors are saying about stocks in your watchlist
Recently Viewed
SVRA
Savara
SHW
Sherwin-Williams Com
CVNA
Carvana Co.
VSAT
ViaSat
LUMN
Lumen Technologies
Most Trending
-2.92%
-2.08%
+9.79%
-19.01%
-3.34%
SVRA
Savara
$2.28
Chart
$3.05 (-25.25%)
$2.6 (-12.31%)
$2.88 (-20.83%)
$4.08 (-44.12%)
FIND US ON
Join over 10,000+ subscribers who value exclusive insights. Stay ahead in the stock market! Enter your email for daily alerts
Stay ahead of the market
Market trends
Investment tips
Market analysis service
Future potential
Informed investment decisions
Investment analysis
IInvestment strategies
In-depth stock analysis
Performance analysis
Stock market insights
Financial trends analysis
Recently Viewed
SVRA
Savara
SHW
Sherwin-Williams Com
CVNA
Carvana Co.
VSAT
ViaSat
LUMN
Lumen Technologies
Most Trending
-2.92%
-2.08%
+9.79%
-19.01%
-3.34%
SVRA
Savara
Current Price
$2.28
Login to view Savara (SVRA) recommendation from the last 90 days from financial news and social media.
Chart
$3.05 (-25.25%)
$2.6 (-12.31%)
$2.88 (-20.83%)
$4.08 (-44.12%)
SVRA Latest Headlines
Why Is Rare Lung Disease-Focused Savara Stock Trading Lower On Tuesday?. ) on Tuesday announced that it received a United States Food And Drug Administration (FDA) refusal To File (RTF)) letter regarding the Biologic license application (BLA) for Molbreevi a therapy for treating patients with autoimmune Pulmonary .Autoimmune PAP is a rare lung disease characterized by the abnormal build-up of surfactant .Surfactant consists of proteins and lipids and is an important physiological substance that
Tue May 27, 2025
Savara Announces Participation in Jefferies Global Healthcare Conference. (Nasdaq: ) (the Company) a clinical stage biopharmaceutical company focused on rare respiratory diseases today announced members of the management team will host 1x1 meetings and present at the Jefferies Global Healthcare Conference on June 4 2025 at 9:20am ET/6:20am PT.The live webcast and subsequent replay will be available on the section of the Company'.s corporate website and will be archived ...
Thu May 22, 2025
Savara Inc. (SVRA): Analysts See 212% Upside Potential.
Wed May 21, 2025
Savara Inc. (SVRA): Analysts See 212% Upside Potential.
Wed May 21, 2025
Savara Inc. (SVRA): Analysts See 212% Upside Potential.
Wed May 21, 2025
Savara Announces Participation in the H.C. Wainwright & Co. 3rd Annual BioConnect Investor Conference. (Nasdaq: ) (the Company) a clinical stage biopharmaceutical company focused on rare respiratory diseases today announced members of the management team will host 1x1 meetings and present at the H.C. Wainwright &. Co. 3rd Annual BioConnect Investor Conference on May 20 2025 at 4:30pm ET/1:30pm PT.The live webcast and subsequent replay will be available on the section of the Company'.s c
Mon May 12, 2025
FIND US ON
Unlock the knowledge that 10,000+ subscribers already cherish. Join for exclusive insights and stay ahead in the stock game! Enter your email to receive daily alerts
In-depth stock analysis
Informed investment decisions
Stock market insights
Stock trading tips
SVRA Stock trends
SVRA Stock performance
SVRA Stock analysis
SVRA investment strategies
Disclaimer:
Past performance, whether from actual results or historical strategy tests, does not guarantee future success. The displayed outcomes are based on strategies not previously available to investors and do not depict the returns achieved by any specific investor.
The Readiness Indicators, Sentiment Indicators, and overall score are derived from a model retrospectively applied using historical data. This model relies on assumptions inherent to it, which may or may not be verifiable and carry potential risks, including losses.
Engaging in active trading may not be suitable for individuals with limited resources, minimal investment or trading experience, or a low-risk tolerance. Proceed with caution as your capital is exposed to risks.
Please note that no offer or solicitation to buy or sell securities, securities derivatives of future products of any kind, or any type of trading or invesment advise, recommendation or strategy, is made, given or endorsed by StocksRunner including any of their affiliates ("TS").
This information is provided for illustrative purposes only. You should not rely on any advice and/or information contained in this website and before making any investment decision. we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice.
Hover over the category for more information
